$TTPH Tetraphase Pharmaceuticals - Pipeline

$TTPH Tetraphase Pharmaceuticals - Pipeline Drugs



PIPELINE
Since inception, Tetraphase has been using its proprietary chemistry technology to build a pipeline of antibiotic candidates to address the serious and growing unmet medical need in the treatment of multidrug-resistant bacterial infections.

ERAVACYCLINE
Eravacycline is our lead product candidate being developed as a broad-spectrum antibiotic for the treatment of life-threatening infections, including those caused by multidrug-resistant (MDR) Gram-negative bacteria. Eravacycline is a novel, fully-synthetic tetracycline antibiotic in a phase 3 program called IGNITE (Investigating Gram-negative Infections Treated with Eravacycline) for the treatment of complicated intra-abdominal infections and complicated urinary tract infections. The FDA has granted Qualified Infectious Disease Product (QIDP) and Fast Track designations for eravacycline for both indications.

TP-271
TP-271 is being developed to combat respiratory disease caused by bacterial biothreats and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia (CABP). TP-271 is a novel, fully-synthetic tetracycline antibiotic in phase 1 clinical development. We are developing TP-271 with funding from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases which supports preclinical development, manufacturing and phase 1 clinical, safety and pharmacokinetic evaluations. The FDA has granted QIDP and Fast Track designations for TP-271 for the treatment of community-acquired bacterial pneumonia.

TP-6076
Our proprietary chemistry technology has fueled the discovery and development of additional tetracycline-derived compounds effective against the most urgent multidrug-resistant Gram-negative bacterial health threats identified by the CDC in a September 2013 report. Pathogens targeted include carbapenem-resistant strains of Klebsiella pneumoniae, Acinetobacter baumannii and Escherichia coli. We have generated compounds with potent activity against a broad range of these pathogens. TP-6076 has been selected as a lead candidate from this program and it is currently being evaluated in a phase 1 clinical trial.